日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

自体多抗原靶向T细胞疗法治疗胰腺癌:一项1/2期试验

Musher, Benjamin L; Vasileiou, Spyridoula; Smaglo, Brandon G; Robertson, Catherine S; Wu, Mengfen; Wang, Tao; Watanabe, Ayumi; Kuvalekar, Manik; Velazquez, Yovana; Ketkar, Shamika; Doheyan, Tamadar Al; Papayanni, Penelope G; Shah, Aakash; Lapteva, Natalia; Grilley, Bambi J; Van Buren, George; Lulla, Premal D; Heslop, Helen E; Rooney, Cliona M; Brenner, Malcolm K; Leen, Ann M

Macrophages as gatekeepers of glioma progression

巨噬细胞作为胶质瘤进展的守门人

Rooney, Cliona M; Mahdi, Jasia

Consensus on the key characteristics of metabolism disruptors

关于代谢干扰物关键特征的共识

La Merrill, Michele A; Smith, Martyn T; McHale, Cliona M; Heindel, Jerrold J; Atlas, Ella; Cave, Matthew C; Collier, David; Guyton, Kathryn Z; Koliwad, Suneil; Nadal, Angel; Rhodes, Christopher J; Sargis, Robert M; Zeise, Lauren; Blumberg, Bruce

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control

组成型IL-7信号传导促进CAR-NK细胞在实体瘤微环境中的存活,但会削弱肿瘤控制。

Dysthe, Matthew; Navin, Ishwar; van Leeuwen, Dayenne; Pineda, Josue; Baumgartner, Corrine; Rooney, Cliona M; Parihar, Robin

Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

EBV相关淋巴瘤患者接受EBVST免疫治疗后,针对EBV蛋白质组的差异性抗体反应

Sarathkumara, Yomani D; Van Bibber, Nathan W; Liu, Zhiwei; Heslop, Helen E; Rouce, Rayne H; Coghill, Anna E; Rooney, Cliona M; Proietti, Carla; Doolan, Denise L

Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial

在 1 期临床试验中对 IL-7 增强的 GD2.CART 产品进行多参数分析

Sarah Schulenberg ,Martí Farrera-Sal ,Michelle Loeser ,Lukas Ehlen ,Stephan Schlickeiser ,Samira Picht ,Lena Peter ,Marco Mai ,Candise L Tat ,Jacqueline Keye ,Desiree Kunkel ,Frank Lin ,Cliona M Rooney ,Bilal Omer ,Michael Schmueck-Henneresse

Mapping assays to the key characteristics of carcinogens to support decision-making

将检测方法与致癌物的关键特征进行比对,以支持决策制定

Rigutto, Gabrielle; McHale, Cliona M; Singam, Ettayapuram Ramaprasad Azhagiya; Rana, Iemaan; Zhang, Luoping; Smith, Martyn T

Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models

新型OX40和4-1BB衍生间隔臂增强了CD30阳性淋巴瘤模型中CD30 CAR的活性和安全性

Lindsay Kua ,Chee Hoe Ng ,Jin Wei Tan ,Hwee Ching Tan ,Cheah Chen Seh ,Fiona Wong ,Richard Ong ,Cliona M Rooney ,Joel Tan ,Qingfeng Chen ,Ivan D Horak ,Kar Wai Tan ,Lionel Low

Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

同时靶向 EBV 裂解抗原和潜伏期抗原可增强 T 细胞对抗淋巴瘤的效力

Sandhya Sharma, Naren U Mehta, Tim Sauer, Lisa A Rollins, Dirk P Dittmer, Cliona M Rooney

Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma

抗排斥 CD30.CAR 修饰的 Epstein-Barr 病毒特异性 T 细胞作为 CD30+ 淋巴瘤的现成平台

David H Quach, Haran R Ganesh, Yolanda D Briones, Nazila Nouraee, Audrey Ma, Yezan F Hadidi, Sandhya Sharma, Cliona M Rooney